Literature DB >> 8383655

The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.

F Sörgel1, M Kinzig.   

Abstract

The pharmacokinetic properties of piperacillin/tazobactam are summarized. The data on piperacillin show that the behaviour of this well established agent is the same when given in combination with tazobactam as when given alone. Tazobactam shows pharmacokinetic characteristics typical of a beta-lactam compound. It distributes mainly into the extracellular space and shows typical tissue penetration behaviour. The tissue concentrations of piperacillin and tazobactam and their pharmacokinetic profiles in plasma and tissues encourage the view that the synergy observed in vitro will be reflected in clinical use.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8383655     DOI： 10.1093/jac/31.suppl_a.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  56 in total

1.  Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Michael Schleimer; Jill Sauer; Anthony Man; Norman Nashed; Thomas Brown; Antonio Perez; Erhard Weidekamm; Péter Kovács
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Assessment of biliary excretion of piperacillin-tazobactam in humans.

Authors:  J F Westphal; J M Brogard; F Caro-Sampara; M Adloff; J F Blicklé; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Tolerability of piperacillin/tazobactam in children and adolescents after high dose radio-/chemotherapy and autologous stem cell transplantation.

Authors:  W Nürnberger; H Bönig; S Burdach; U Göbel
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

7.  Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.

Authors:  Eleftheria Mavridou; Ria J B Melchers; Anita C H A M van Mil; E Mangin; Mary R Motyl; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

8.  Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Authors:  Cornelia B Landersdorfer; Jurgen B Bulitta; Carl M J Kirkpatrick; Martina Kinzig; Ulrike Holzgrabe; George L Drusano; Ulrich Stephan; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

9.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.